Currently out of the existing stock ratings of Greg Harrison, 74 are a BUY (69.16%), 26 are a HOLD (24.3%), 7 are a SELL (6.54%).

Greg Harrison

Work Performance Price Targets & Ratings Chart

Analyst Greg Harrison, currently employed at BAML, carries an average stock price target met ratio of 59.3% that have a potential upside of 38.38% achieved within 128 days. Previously, Greg Harrison worked at SCOTIABANK.

Greg Harrison’s has documented 210 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RCKT, Rocket Pharmaceuticals at 25-Jul-2025.

Wall Street Analyst Greg Harrison

Analyst best performing recommendations are on OMER (OMEROS).
The best stock recommendation documented was for OMER (OMEROS) at 11/8/2022. The price target of $3 was fulfilled within 1 day with a profit of $0.2 (6.25%) receiving and performance score of 62.5.

Average potential price target upside

of $24.73 (6.1%) on VRTX (VERTEX PHARMACEUTICALS).
of $25.22 (9.3%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $22.6 (30.02%) on NLTX (NEOLEUKIN THERAPEUTICS).

ATHX Athersys NKTR Nektar Therapeutics RCKT Rocket Pharmaceuticals TVTX Travere Therapeutics AGIO Agios Pharm RDUS Schnitzer Steel Industries STOK Stoke Therapeutics OMER Omeros EDIT Editas Medicine NLTX Neoleukin Therapeutics LQDA Liquidia Technologies BBIO BridgeBio Pharma ISEE IVERIC bio BEAM Beam Therapeutics UTHR United Therapeutics NTLA Intellia Therapeutics SGMO Sangamo Therapeutics ALNY Alnylam Pharmaceuticals APLS Apellis Pharmaceuticals KROS Keros Therapeutics VRTX Vertex Pharmaceuticals IRON Disc Medicine

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Greg Harrison (BAML)